Concepedia

Publication | Open Access

Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants

DOIFull Paper Access

72

Citations

31

References

2007

Year

Teresa Guida, Suresh Anaganti, Livia Provitera, Richard Gedrich, Elizabeth Sullivan, Scott M. Wilhelm, Massimo Santoro, Francesca Carlomagno
Clinical Cancer Research

Abstract

Sorafenib might be a promising anticancer agent for patients carrying KIT and PDGFRbeta gatekeeper mutations.

References

YearCitations

Page 1